XML 60 R48.htm IDEA: XBRL DOCUMENT
v3.26.1

Income tax expense (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Income taxes paid (refund) [abstract] |
Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes | The table below shows the allocation of income tax expense between current and deferred taxes:
(€ million) | June 30, 2026 (6 months) | June 30, 2025 (6 months) |  |
Current taxes | (1,089) |  | (1,202) |  |  |
Deferred taxes | 218 |  | 491 |  |  |
Total | (871) |  | (711) |  |  |
Income before tax and investments accounted for using the equity method | 2,840 |  | 3,582 |  |  |
Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate | The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:
(as a percentage) | June 30, 2026 (6 months) (a) | June 30, 2025 (6 months)(a) |  |  |
Standard tax rate applicable in France | 25.8 |  | 25.8 |  |  |  |
Difference between the standard French tax rate and the rates applicable to Sanofi (b) | (17.9) |  | (7.3) |  |  |  |
Tax effect related to amlitelimab (c) | 19.3 |  | — |  |  |  |
Revisions to tax exposures and settlements of tax disputes | 1.8 |  | 2.3 |  |  |  |
Other (d) | 1.5 |  | (1.0) |  |  |  |
Effective tax rate | 30.6 |  | 19.8 |  |  |  |
(a)Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.). (b)This line reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France, and the impact of patent-favorable tax regimes. The 2025 component of the temporary exceptional corporate income tax surcharge, introduced under the 2026 French Finance Act, is included in the tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34. (c) This relates to the non-deductibility of the impairment loss on the amlitelimab intangible asset (see Note B.4.), and associated effects on deferred tax assets. (d) For the six months ended June 30, 2026, this line includes a tax expense of €57 million representing the estimated impact of Pillar Two based on Sanofi’s current understanding of Pillar Two rules, compared with €17 million for the six months ended June 30, 2025.

X
- References No definition available. + Details
Name: | ifrs-full_IncomeTaxesPaidRefundAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of allocation of income tax between current and deferred taxes. + References No definition available. + Details
Name: | sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of reconciliation of average effective tax rate and applicable tax rate. + References No definition available. + Details
Name: | sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration